Sign in6 stories
The company finalized terms on September 29, 2026 for an offering of 36 million shares plus warrants, with proceeds aimed at funding a planned Phase 3 trial in head and neck cancer.
SEC filing (2)
The offering combines stock and warrants whose exercisability depends on a shareholder vote and the timing of a Phase 1 survival readout expected in the first half of 2027.
SEC filing
The company filed a prospectus supplement on September 29, 2026 cutting its ATM sales capacity to zero, though no shares had been sold under the program.
SEC filing
Updated results show a 36% response rate and 79% one-year survival probability, supporting plans for a Phase 3 trial starting mid-2027.
SEC filing
The board also named co-founder John Flavin Lead Independent Director as the company nears key MICVO clinical data readouts.
SEC filing
Updated monotherapy data are still expected this fall and combination data in Q4 2026, after a financing extended cash runway into Q2 2027.
SEC filing